Stocks · News reference
8-K filing — IMMUCELL CORP /DE/ (ICCC)
Filed: 2026-10-13 AccNo: 0001437749-26-032465 Size: 178 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
ImmuCell Sees Q3 Sales $8.000M
ImmuCell (NASDAQ:ICCC) sees Q3 sales of $8.000 million.
ImmuCell Reports Q3 Preliminary Sales Of $8M, Up 46% YoY
ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity,